Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences is a promising company with a strong intellectual property portfolio, with a potential for significant growth in the retinal medicines market. The positive results from the Phase 3 GLOW2 study for Zenkuda in patients with NPDR and the ongoing DAYBREAK study for wet AMD, along with the company's strategic decision to include Zenkuda in the DAYBREAK study, gives confidence in the long-term potential of both Zenkuda and KSI-501. The company also has a robust pipeline and a strong presence in the retinal medicine space, making it a favorable investment for long-term growth.

Bears say

Kodiak Sciences is a pre-commercial biopharmaceutical company that has developed a proprietary ABC platform for retinal medicines. While Kodiak's investigational medicines show promise in addressing unmet needs in retinal diseases, the company faces significant challenges in bringing its products to market, including competition from other big biopharma companies, potential manufacturing difficulties, and financing risks. These factors contribute to the analyst's negative outlook on the stock.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.